Summit Therapeutics Inc. (SMMT) SEC Filings

Summit Therapeutics Inc. (SMMT) reported that partner Akeso Inc. presented updated overall survival data from the randomized, double-blind Phase III HARMONi-2 trial of ivonescimab versus pembrolizumab in PD-L1–positive advanced non-small cell lung cancer in China.

In the intention-to-treat population of 398 patients and a median follow-up of 36.0 months, ivonescimab monotherapy achieved a median overall survival of 30.8 months versus 22.6 months for pembrolizumab, with an overall survival hazard ratio of 0.73 (95% CI: 0.57–0.95; p=0.009). A notable benefit was seen in the PD-L1 high subgroup (score ≥50%; n=168) with a hazard ratio of 0.58 (95% CI: 0.38–0.89), and positive trends were reported across PD-L1 low and histology subgroups.

Ivonescimab showed an acceptable and manageable safety profile, with serious treatment-related adverse events in 29.9% of ivonescimab patients versus 21.6% on pembrolizumab, and low discontinuation rates in both arms. Akeso received Chinese marketing authorization for ivonescimab in 2025 based on HARMONi-2, while Summit is running multiple global Phase III studies, including the HARMONi-7 trial targeting about 780 patients and a separate HARMONi study that has led to a Biologics License Application accepted by the FDA with a goal PDUFA date of November 14, 2026.

Summit Therapeutics Inc. (SMMT) reported that partner Akeso Inc. announced positive overall survival results from the randomized, double-blind Phase III HARMONi-2 study of ivonescimab monotherapy versus pembrolizumab in PD-L1–positive advanced non-small cell lung cancer in China. Ivonescimab showed a statistically significant overall survival benefit in this preplanned analysis.

Ivonescimab had previously met the primary endpoint of progression-free survival in HARMONi-2, with a hazard ratio of 0.51 (95% CI: 0.38–0.69; p<0.0001), supporting China marketing authorization granted to Akeso in April 2025. Summit highlights a broad late-stage program, including its own positive Phase III HARMONi trial and an accepted Biologics License Application with a goal PDUFA date of November 14, 2026.

Across Summit- and Akeso-sponsored programs, ivonescimab is being studied in multiple Phase III trials in NSCLC and other tumors, with five Phase III trials reported as positive to date and extensive clinical and commercial experience in China. Ivonescimab remains investigational in Summit’s territories, including the United States and Europe.

Summit Therapeutics Inc. (SMMT) reported that its partner Akeso Inc. announced positive topline results from the Phase III HARMONi-GI1 trial in first-line advanced biliary tract cancer. Ivonescimab plus chemotherapy showed statistically significant and clinically meaningful superiority in the primary endpoint of overall survival versus durvalumab plus chemotherapy, and the study also met key secondary endpoints of progression-free survival and objective response rate in a pre-specified interim analysis. HARMONi-GI1 was conducted in China by Akeso, which generated, managed, and analyzed all data; detailed safety and efficacy results are expected at an upcoming medical congress and in a peer-reviewed journal. Ivonescimab (SMT112 in Summit’s territories) remains investigational and is not approved in Summit’s license regions, while a Biologics License Application for ivonescimab in NSCLC based on the HARMONi trial has been accepted by the FDA with a PDUFA goal date of November 14, 2026.

Summit Therapeutics Inc. is expanding its global, registration-enabling development program for ivonescimab into urothelial carcinoma with the initiation of the multi-regional Phase II/III HARMONi-GU1 study. This randomized trial will evaluate ivonescimab plus the antibody-drug conjugate enfortumab vedotin versus pembrolizumab plus enfortumab vedotin as first-line therapy for previously untreated locally advanced or metastatic urothelial carcinoma.

HARMONi-GU1 intends to enroll approximately 800 patients through Phase III, with Phase II identifying the recommended Phase III dose. The primary Phase III endpoints are progression-free survival and overall survival, and global clinical trial site activations are planned to begin by the fourth quarter of 2026. With this study, ivonescimab is being evaluated in 16 Phase III clinical trials across multiple tumor types, alongside a Biologics License Application in NSCLC that has an FDA PDUFA goal date of November 14, 2026.

Summit Therapeutics Inc. entered into a distribution agreement with J.P. Morgan Securities LLC allowing at the market offerings of its common stock with an aggregate offering price of up to $380,000,000. Under this arrangement, J.P. Morgan, as sales agent, may sell shares from time to time at market or negotiated prices and will receive a commission of up to 3.0% of the gross sales price per share. Summit has no obligation to sell shares and may suspend offers at any time. Any issuances will occur under its effective Form S-3 registration statement (File No. 333-296642) and a related prospectus supplement filed on July 23, 2026.

Summit Therapeutics Inc. is establishing an at-the-market equity program to issue and sell up to $380,000,000 of common stock through J.P. Morgan Securities LLC as sales agent. Shares may be sold on The Nasdaq Global Market under the symbol SMMT or through other permitted transactions, with the Sales Agent earning up to 3.0% of the gross sales price.

Assuming sales at $14.74 per share, the company illustrates issuance of 25,780,189 shares versus 793,120,362 shares outstanding as of June 30, 2026. Net tangible book value would rise from $0.79 to $1.22 per share, causing illustrative dilution of $13.52 per share to new investors. Proceeds are intended primarily to fund development of lead oncology candidate ivonescimab, including NSCLC, CRC and other solid-tumor trials, and for working capital.

Summit discloses substantial doubt about its ability to continue as a going concern because existing cash and investments do not fund 12 months of planned operations, making additional capital raises important. Recent HARMONi study data showed a hazard ratio of 0.76 for overall survival with ivonescimab and an acceptable safety profile, and Summit entered a clinical collaboration with Arcus Biosciences to evaluate ivonescimab plus casdatifan in clear cell renal cell carcinoma.

Summit Therapeutics Inc. reported a net loss of $215,700 for the three months and $405,124 for the six months ended June 30, 2026, compared with losses of $565,708 and $628,621 a year earlier. Operating expenses were $220,496 for the quarter, driven by research and development of $157,733 and general and administrative costs of $62,763. Stock-based compensation remained significant at $68,706 for the quarter, though lower than the prior-year period.

Cash used in operating activities reached $263,415 in the first half of 2026. As of June 30, 2026, cash and cash equivalents were $419,365 and short-term investments were $271,313, against an accumulated deficit of $2,699,283. Management states that this liquidity is not sufficient to fund planned operations for at least one year and that these conditions raise substantial doubt about the company’s ability to continue as a going concern, making additional financing critical.

The company’s strategy centers on ivonescimab, a bispecific PD-1/VEGF-A antibody being developed across multiple Phase III trials in non-small cell lung and colorectal cancers. In EGFR‑mutated NSCLC after EGFR-TKI therapy, the HARMONi trial showed a progression free survival hazard ratio of 0.52, while overall survival trended favorably but did not reach statistical significance. A Biologics License Application for this setting has been accepted by the FDA with a Prescription Drug User Fee Act goal action date of November 14, 2026; the FDA has cautioned that a statistically significant overall survival benefit is expected for approval.

Summit Therapeutics reported Q2 2026 results and progress on its ivonescimab program. GAAP net loss was $215.7 million, or $(0.28) per share, versus $565.7 million, or $(0.76) per share, a year earlier. Non-GAAP net loss was $147.0 million, or $(0.19) per share. Cash, cash equivalents and short-term investments were $690.7 million at June 30, 2026, compared with $713.4 million at December 31, 2025, supported by $230.8 million of Q2 gross proceeds from its ATM facility and a further $68.4 million raised afterward; the company reported no debt.

GAAP operating expenses were $220.5 million in Q2 2026, down from $568.4 million due mainly to lower stock-based compensation, while non-GAAP operating expenses rose to $151.8 million from $89.6 million as ivonescimab development expanded. For the first half of 2026, net cash used in operating activities increased to $263.4 million, partly offset by $234.9 million of cash provided by financing activities.

Summit highlighted ivonescimab as its lead asset. An updated HARMONi overall survival analysis showed a hazard ratio of 0.76 for the intent-to-treat population and for Asian and Western subgroups, with Western patients reaching 23.2 months of median follow-up and Asian patients 32.7 months. The Biologics License Application for ivonescimab plus chemotherapy in EGFR-mutated non-squamous non-small cell lung cancer has a Prescription Drug User Fee Act goal action date of November 14, 2026. In China’s HARMONi-6 Phase III trial, ivonescimab plus chemotherapy achieved an overall survival hazard ratio of 0.66 versus tislelizumab plus chemotherapy. Enrollment in the global HARMONi-3 first-line NSCLC study is complete, with key progression-free survival and interim overall survival analyses expected between the second half of 2026 and the first half of 2027. Summit also sold its ridinilazole antibiotic asset to Biossil for $500,000 upfront, up to $104.5 million in milestones, and tiered royalties, and expanded collaborations with Arcus, Revolution Medicines, GORTEC, GSK and multiple investigator-sponsored studies.

Summit Therapeutics Inc. reported updated overall survival results from its global Phase III HARMONi trial of ivonescimab plus platinum-doublet chemotherapy versus chemotherapy alone in patients with EGFR‑mutated, locally advanced or metastatic non‑squamous NSCLC previously treated with a third‑generation EGFR TKI. The study had already shown a statistically significant benefit in progression‑free survival, one of its two primary endpoints along with overall survival.

With a June 2026 data cut, a hazard ratio of 0.76 for overall survival was observed in both the full intention‑to‑treat population and the western patient subgroup, indicating a favorable survival trend compared with placebo plus chemotherapy. Earlier analyses showed hazard ratios of 0.79 at the April 2025 primary OS analysis and 0.78 at the September 2025 analysis, when median OS was 16.8 months for ivonescimab plus chemotherapy versus 14.0 months for placebo plus chemotherapy. Western follow‑up increased from 9.2 to 13.7 to 23.2 months across these analyses, while Asian patients remained locked at 32.7 months of follow‑up. Ivonescimab continued to show an acceptable, manageable safety profile consistent with prior Phase III data, with no additional safety signals. These updated OS data have been provided to the FDA, where a Biologics License Application based on HARMONi is under review with a PDUFA goal action date of November 14, 2026.